

26<sup>th</sup> April, 2019

The Dy. General Manager (Listing Dept.)  
BSE Limited  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub.: Intimation**

---

This is to inform you that the audit at Indrad Plant of the Company was carried out by USFDA in the month of April, 2019. We have received certain observations which are procedural in nature and the Company is confident of addressing them satisfactorily.

The above is for your information.


Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL

 VP (LEGAL) & COMPANY SECRETARY